In particular, CD8+ TILs tend to exhibit a dominant phenotype that varies significantly across tumors, whereas CD4+ TILs show a more uniform phenotype across patients, perhaps reflecting distinct responses to the metabolic selection pressures within the tumor milieu. This evidence concerns the gene CD4 and neoplasm.